Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Target Raised at JPMorgan Chase & Co.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price hoisted by equities research analysts at JPMorgan Chase & Co. from $950.00 to $1,050.00 in a report released on Friday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 13.16% from the stock’s previous close.

A number of other research analysts have also weighed in on REGN. Evercore increased their price objective on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a report on Friday, July 31st. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $660.00 to $978.00 in a report on Thursday, October 15th. Raymond James Financial upped their target price on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Piper Sandler increased their price target on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. Finally, Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $872.00.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $927.89 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The stock’s fifty day moving average price is $793.30 and its 200 day moving average price is $738.05. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $935.35. The company has a market cap of $95.54 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same quarter last year, the business posted $11.83 EPS. The firm’s quarterly revenue was up 36.3% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Andrew Murphy sold 4,147 shares of the company’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the sale, the insider owned 47,833 shares in the company, valued at $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the transaction, the executive vice president owned 12,003 shares of the company’s stock, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock worth $6,506,845 over the last ninety days. 6.97% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in REGN. Boston Trust Walden Corp boosted its stake in shares of Regeneron Pharmaceuticals by 794.1% during the 3rd quarter. Boston Trust Walden Corp now owns 10,667 shares of the biopharmaceutical company’s stock worth $8,088,000 after acquiring an additional 9,474 shares in the last quarter. Chicago Partners Investment Group LLC raised its holdings in Regeneron Pharmaceuticals by 29.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,865 shares of the biopharmaceutical company’s stock worth $2,306,000 after purchasing an additional 656 shares during the period. Covestor Ltd raised its holdings in Regeneron Pharmaceuticals by 31.5% in the 3rd quarter. Covestor Ltd now owns 171 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 41 shares during the period. Compass Financial Management LLC grew its stake in Regeneron Pharmaceuticals by 4,526.2% in the 3rd quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock valued at $2,280,000 after acquiring an additional 2,942 shares during the period. Finally, Pzena Investment Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $310,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly results: Regeneron reported $5.12 billion in revenue, up 36% year over year and above the $4.58 billion analyst consensus. Adjusted earnings of $20.07 per share also exceeded expectations of $16.51. Regeneron revenue jumps 36% on a bigger Sanofi profit share
• Positive Sentiment: Dupixent remains the primary growth engine: Global quarterly Dupixent sales rose 35% to approximately $6.5 billion, reinforcing the strength of Regeneron’s collaboration with Sanofi and supporting expectations for continued earnings growth. Regeneron: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pipeline and commercial catalysts: Investors highlighted encouraging Libtayo data in high-risk skin cancer, an expanded BARDA supply agreement for Ebola treatment, and management’s comments about a deep development pipeline. Ongoing share repurchases may also support per-share results. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, or $3.76 annualized, payable December 3 to shareholders of record November 20. The approximately 0.4% yield is modest but signals continued shareholder returns.
• Neutral Sentiment: Citigroup has forecast further appreciation, while the stock’s breakout to a two-year and 52-week high reflects strong investor momentum. However, the recent rally raises questions about how much future growth is already reflected in the valuation. Regeneron Bolts Higher on Dupixent Dominance
• Negative Sentiment: At roughly $928 per share, Regeneron has risen substantially and may face profit-taking or valuation pressure if future results do not maintain the current pace of growth. Regeneron Stock Looks At A Discount To Earnings

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.